Literature DB >> 29116382

Selective dorsal rhizotomy for the treatment of severe spastic cerebral palsy: efficacy and therapeutic durability in GMFCS grade IV and V children.

Daniel D'Aquino1, Ahmad A Moussa2,3, Amr Ammar2, Harshal Ingale2, Michael Vloeberghs2.   

Abstract

BACKGROUND: Selective dorsal rhizotomy (SDR) has been established as an effective surgical treatment for spastic diplegia. The applicability of SDR to the full spectrum of spastic cerebral palsy and the durability of its therapeutic effects remain under investigation. There are currently limited data in the literature regarding efficacy and outcomes following SDR in Gross Motor Function Classification System (GMFCS) IV and V patients. Intrathecal baclofen has traditionally been the surgical treatment of choice for these patients. When utilised primarily as a treatment for the relief of spasticity, it is proposed that SDR represents a rational and effective treatment option for this patient group. We report our outcomes of SDR performed on children with severe cerebral palsy (GMFCS grade IV and V). The commensurate improvement in upper as well as lower limb spasticity is highlighted. Apparent benefit to urological function following SDR in this patient group is also discussed.
METHOD: A retrospective review of prospectively collected data for 54 paediatric patients with severe cerebral palsy (GMFCS IV-V) who received SDR plus specialised physiotherapy. Mean age was 10.2 years (range, 3.0-19.5). SDR guided by electrophysiological monitoring was performed by a single experienced neurosurgeon. All subjects received equivalent physiotherapy. The primary outcome measure was change to the degree of spasticity following SDR. Spasticity of upper and lower limb muscle groups were quantified and standardised using the Ashworth score. Measures were collected at baseline and at 2-, 8- and 14-month postoperative intervals. In addition, baseline and 6-month postoperative urological function was also evaluated as a secondary outcome measure.
RESULTS: The mean lower limb Ashworth score at baseline was 3.2 (range, 0-4). Following SDR, significant reduction in lower limb spasticity scores was observed at 2 months and maintained at 8 and 14 months postoperatively (Wilcoxon rank, p < 0.001). The mean reduction at 2, 8 and 14 months was 3.0, 3.2 and 3.2 points respectively (range, 1-4), confirming a sustained improvement of spasticity over a 1-year period of follow-up. Significant reduction in upper limb spasticity scores following SDR was also observed (mean, 2.9; Wilcoxon rank, p < 0.001). Overall, the improvement to upper and lower limb tone following SDR-generally to post-treatment Ashworth scores of 0-was clinically and statistically significant in GMFCS IV and V patients. Urological assessment identified pre-existing bladder dysfunction in 70% and 90% of GMFCS IV and V patients respectively. Following SDR, improvement in urinary continence was observed in 71% of affected GMFCS IV and 42.8% of GMFCS V patients. No serious postoperative complications were identified.
CONCLUSIONS: We conclude that SDR is safe and-in combination with physiotherapy-effectively reduces spasticity in GMFCS grade IV and V patients. Our series suggests that spastic quadriplegia is effectively managed with significant improvements in upper limb spasticity that are commensurate with those observed in lower limb muscle groups. These gains are furthermore sustained more than a year postoperatively. In light of these findings, we propose that SDR constitutes an effective treatment option for GMFCS IV and V patients and a rational alternative to intrathecal baclofen.

Entities:  

Keywords:  Functional; GMFCS; Intrathecal baclofen; Movement disorder; Non-ambulant; Paediatric; Selective dorsal rhizotomy; Spasticity

Mesh:

Year:  2017        PMID: 29116382     DOI: 10.1007/s00701-017-3349-z

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  7 in total

1.  Improving access to selective dorsal rhizotomy for children with cerebral palsy.

Authors:  Benjamin Davidson; Darcy Fehlings; Golda Milo-Manson; George M Ibrahim
Journal:  CMAJ       Date:  2019-11-04       Impact factor: 8.262

2.  Predictors of postoperative complications after selective dorsal rhizotomy.

Authors:  Johannes Wach; Ömer Can Yildiz; Sevgi Sarikaya-Seiwert; Hartmut Vatter; Hannes Haberl
Journal:  Acta Neurochir (Wien)       Date:  2020-07-20       Impact factor: 2.216

Review 3.  Interventional Approaches to Pain and Spasticity Related to Cerebral Palsy.

Authors:  Jacquelin Peck; Ivan Urits; Hisham Kassem; Christopher Lee; Wilton Robinson; Elyse M Cornett; Amnon A Berger; Jared Herman; Jai Won Jung; Alan D Kaye; Omar Viswanath
Journal:  Psychopharmacol Bull       Date:  2020-10-15

4.  Australian children undergoing selective dorsal rhizotomy: protocol for a national registry of multidimensional outcomes.

Authors:  Jennifer Lewis; Natasha Bear; Felicity Baker; Adam Fowler; Olivia Lee; Kim McLennan; Emma Richardson; Adam Scheinberg; Nadine Smith; Pam Thomason; Andrew Tidemann; Meredith Wynter; Simon Paget
Journal:  BMJ Open       Date:  2019-05-01       Impact factor: 2.692

5.  Selective dorsal rhizotomy in cerebral palsy spasticity - a newly established operative technique in Slovenia: A case report and review of literature.

Authors:  Tomaz Velnar; Peter Spazzapan; Zoran Rodi; Natasa Kos; Roman Bosnjak
Journal:  World J Clin Cases       Date:  2019-05-26       Impact factor: 1.337

6.  Selective dorsal rhizotomy in ambulant children with cerebral palsy.

Authors:  K K Wang; M E Munger; B P-J Chen; T F Novacheck
Journal:  J Child Orthop       Date:  2018-10-01       Impact factor: 1.548

7.  Whether the newly modified rhizotomy protocol is applicable to guide single-level approach SDR to treat spastic quadriplegia and diplegia in pediatric patients with cerebral palsy?

Authors:  Qijia Zhan; Xidan Yu; Wenbin Jiang; Min Shen; Shuyun Jiang; Rong Mei; Junlu Wang; Bo Xiao
Journal:  Childs Nerv Syst       Date:  2019-09-09       Impact factor: 1.475

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.